Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, April 24, 2014, 69 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $101.08 to $41,000,000.00.

Highlighted Stocks Traded by Insiders:

Select Comfort (SCSS) - FREE Research Report

Kimball Mark A, who is SVP Chief Legal & Risk Officer at Select Comfort, sold 20,000 shares at $19.31 on April 24, 2014. Following this transaction, the SVP Chief Legal & Risk Officer owned 117,919 shares meaning that the stake was reduced by 14.5% with the 20,000-share transaction.

The shares most recently traded at $18.63, down $0.68, or 3.63% since the insider transaction. Historical insider transactions for Select Comfort go as follows:

  • 4-Week # shares bought: 469
  • 4-Week # shares sold: 4,000
  • 12-Week # shares bought: 469
  • 12-Week # shares sold: 4,000
  • 24-Week # shares bought: 469
  • 24-Week # shares sold: 41,661

The average volume for Select Comfort has been 991,600 shares per day over the past 30 days. Select Comfort has a market cap of $1.0 billion and is part of the consumer goods sector and consumer durables industry. Shares are down 9.77% year-to-date as of the close of trading on Thursday.

Select Comfort Corporation, together with its subsidiaries, provides sleep solutions and services in the United States. The company manufactures, markets, and retails beds and bedding products, such as mattresses, pillows, sheets, adjustable bases, and other bedding products. The company has a P/E ratio of 15.8. Currently, there is 1 analyst who rates Select Comfort a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SCSS - FREE

TheStreet Quant Ratings rates Select Comfort as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Select Comfort Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Salix Pharmaceuticals (SLXP) - FREE Research Report

D Alonzo Thomas, who is Director at Salix Pharmaceuticals, sold 11,530 shares at $110.89 on April 24, 2014. Following this transaction, the Director owned 79,179 shares meaning that the stake was reduced by 12.71% with the 11,530-share transaction.

The shares most recently traded at $109.82, down $1.07, or 0.98% since the insider transaction. Historical insider transactions for Salix Pharmaceuticals go as follows:

  • 4-Week # shares sold: 8,463
  • 12-Week # shares sold: 8,463
  • 24-Week # shares sold: 8,463

The average volume for Salix Pharmaceuticals has been 1.1 million shares per day over the past 30 days. Salix Pharmaceuticals has a market cap of $7.0 billion and is part of the health care sector and drugs industry. Shares are up 23.17% year-to-date as of the close of trading on Thursday.

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. The company has a P/E ratio of 52.4. Currently, there are 10 analysts who rate Salix Pharmaceuticals a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SLXP - FREE

TheStreet Quant Ratings rates Salix Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Salix Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Vantiv (VNTV) - FREE Research Report

Stiefler Jeffrey E, who is Director at Vantiv, sold 6,000 shares at $30.03 on April 24, 2014. Following this transaction, the Director owned 89,523 shares meaning that the stake was reduced by 6.28% with the 6,000-share transaction.

The shares most recently traded at $29.61, down $0.42, or 1.43% since the insider transaction. Historical insider transactions for Vantiv go as follows:

  • 4-Week # shares sold: 12,500
  • 12-Week # shares sold: 18.8 million
  • 24-Week # shares sold: 33.9 million

The average volume for Vantiv has been 1.5 million shares per day over the past 30 days. Vantiv has a market cap of $4.2 billion and is part of the services sector and diversified services industry. Shares are down 8.89% year-to-date as of the close of trading on Thursday.

Vantiv, Inc. provides electronic integrated payment processing services in the United States. It operates in two segments, Merchant Services and Financial Institution Services. The company has a P/E ratio of 37.0. Currently, there are 7 analysts who rate Vantiv a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VNTV - FREE

TheStreet Quant Ratings rates Vantiv as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Vantiv Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null